Drug Type Small molecule drug |
Synonyms Alpha-hederin |
Target |
Action inhibitors |
Mechanism SMAD2 inhibitors(Mothers against decapentaplegic homolog 2 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC41H66O12 |
InChIKeyKEOITPILCOILGM-LLJOFIFVSA-N |
CAS Registry27013-91-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hyperlipidemias | China | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | China | 08 Mar 2025 | |
Breast Cancer | Preclinical | Sri Lanka | 12 Apr 2024 | |
Non-Small Cell Lung Cancer | Preclinical | China | 01 Feb 2024 |